RAVENSBURG, Germany--(15th Pharma Congress Production & Technology in Duesseldorf, Germany, March 19 - 20. Vetter, one of the worlds’ leading Contract and Development Manufacturing Organization, will present on a variety of informative core developments critical to the international pharmaceutical and biotech industries. Udo J. Vetter, chairman of the Vetter advisory board, will present the keynote address at the Congress focusing his comments on the future demands and challenges in pharmaceutical manufacturing. Vetter experts will address various topics including the needs for filling monoclonal antibodies, advantages and solutions of restricted access barrier systems (RABS) and the implementation of isolators for sterility tests as well as Vetter’s own supplier management system and the company’s new Center for Visual Inspection and Logistics.)--Changing markets and potential solutions will be the highlight at the
Major changes taking place among the world’s leading pharmaceutical and biotech companies demand creative solutions to complex challenges by the manufacturing industry. The 15th Pharma Congress Production & Technology held in mid-March, will bring together representatives from the private and public sectors to discuss the current market trends. Vetter, an international specialist in aseptic filling, will present on best practices in sterile manufacturing and packaging.
Presenter and topics include Udo J. Vetter, who will be focusing on aseptic manufacturing at the Congress's keynote. The chairman of the Vetter advisory board will be speaking about the current market trends and their long-term effects on sterile production. He will also discuss changing technological and regulatory requirements and how innovative and flexible production plants can provide answers.
Joerg Zimmermann, Director Process Development and Implementation will present two case studies including Vetter’s experiences with fill-and-finish considerations for monoclonal antibodies and how certain challenges are already being met in the early phases. His second case study will cover the function and advantages of the restricted access barrier systems (RABS) in aseptic manufacturing and how to operate a RABS-based line successfully based on real life experience. Mr. Zimmermann will also moderate the ECA Barrier Systems Conference, one of the key sessions of the Congress.
Dr. Andreas Reicke, Team Coordinator at Vetter’s microbiology division will review a case study on the implementation of sterility test isolators. He will talk about regulatory demands and considerations in regards to design, location and utilities as well as project planning from beginning through to implementation.
Uli Kuchenbrod, Director Incoming Goods at Vetter, will give his insights into Vetter‘s supplier management system and incoming inspections as part of quality control. He will also address the operative challenges as well as the strategic considerations between a CDMO and its suppliers.
Thomas Ruebekeil, Director Investment Projects will introduce the new Vetter Ravensburg site. He will present the project plan and best practice as well as provide an update on the Center for Visual Inspection and Logistics including characteristics of the building itself and the use of regenerative energy and how it can be safely and efficiently used in the pharmaceutical sector.
All of the presentations are consistent with the goal of the international event which is to present lectures as technical applications "from users for users", primarily concentrating on their practical benefits.
Vetter is a leading contract development and manufacturing organization (CDMO) that specializes in the aseptic filling of syringes, cartridges and vials. The company has extensive experience with biologics and other complex compounds, including monoclonal antibodies, peptides, interferons and vaccines. Its clientele includes the world’s top 10 pharma/biotech firms and emerging companies alike. A full-service provider, Vetter supports products throughout their lifecycles, from preclinical development through global market supply. Through its U.S. and European facilities, Vetter Development Service provides state-of-the-art support for early-stage products, with seamless transfer at Phase III to Vetter Commercial Manufacturing for large-scale production. The company is the originator of dual-chamber technology, which enables easier, safer lyophilized-drug administration; and is a leader in the use of RABS technology in cleanrooms, which mitigates risk of product contamination during the manufacturing process. Vetter has won numerous awards for innovation and quality, including top prize at the 2012 European Outsourcing Awards for its new high-speed filling line. Headquartered in Ravensburg, Germany, the company employs approximately 3,000 staff across Europe and the United States. For more information about Vetter, visit www.vetter-pharma.com